Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).

[1]  D. Jacobs,et al.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis , 2015, Journal of hypertension.

[2]  A. Folsom,et al.  The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. , 2014, Metabolism: clinical and experimental.

[3]  A. Khera,et al.  Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. , 2013, Journal of the American College of Cardiology.

[4]  J. Coresh,et al.  NH2-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes , 2013, Diabetes.

[5]  N. Cook,et al.  Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. , 2013, Clinical chemistry.

[6]  L. Lind,et al.  Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged ≥ 70 years. , 2013, The American journal of cardiology.

[7]  Thomas J. Wang,et al.  Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  C. Passino,et al.  Circulating forms of the b-type natriuretic peptide prohormone: pathophysiologic and clinical considerations. , 2012, Advances in clinical chemistry.

[9]  D. Jacobs,et al.  Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 mL/min/1.73 m(2): the Multi-Ethnic Study of Atherosclerosis (MESA). , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  G. Pacini,et al.  B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men , 2012, Diabetologia.

[11]  B. Kestenbaum,et al.  Kidney Function Decline in the Elderly: Impact of Lipoprotein-Associated Phospholipase A2 , 2011, American Journal of Nephrology.

[12]  D. Levy,et al.  Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. , 2011, The American journal of cardiology.

[13]  Inês Barroso,et al.  Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population Studies , 2011, PLoS medicine.

[14]  Chia-Jung Lu,et al.  Development of a Novel , 2011 .

[15]  H. Bøtker,et al.  Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients. , 2010, International journal of cardiology.

[16]  D. Jacobs,et al.  The association between physical activity and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. , 2008, American journal of epidemiology.

[17]  W. März,et al.  N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. , 2007, Clinical chemistry.

[18]  D. Phelan,et al.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. , 2007, Journal of cardiac failure.

[19]  W. März,et al.  N-Terminal ProB-Type Natriuretic Peptide Predicts Total and Cardiovascular Mortality in Individuals with or without Stable Coronary Artery Disease : The Ludwigshafen Risk and Cardiovascular Health Study , 2007 .

[20]  Alan H B Wu,et al.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.

[21]  A. Folsom,et al.  Smoking, diabetes, and blood cholesterol differ in their associations with subclinical atherosclerosis: the Multiethnic Study of Atherosclerosis (MESA). , 2006, Atherosclerosis.

[22]  S. Lai,et al.  Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. , 2006, AJR. American journal of roentgenology.

[23]  G. Fonarow,et al.  B-type natriuretic peptide levels in obese patients with advanced heart failure. , 2006, Journal of the American College of Cardiology.

[24]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[25]  R. Sarzani,et al.  Role of the natriuretic peptide system in lipogenesis/lipolysis. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[26]  T. Mueller,et al.  Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. , 2003, Clinical chemistry.

[27]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[28]  J. Karl,et al.  Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. , 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[29]  D. Garbers,et al.  Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. , 1992, The Journal of biological chemistry.

[30]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[31]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.